

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

UNUSUAL PRICE AND TRADING VOLUME MOVEMENT

This statement is made at the request of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board of directors (the “**Board**”) of the Company has noted the increase in the price and trading volume of the shares of the Company today. The Board has also noted certain financial media reporting that according to certain analyst reports on the Company, the management of the Company has indicated a target guidance of 20%-30% profit growth of the Group and 25%-30% sales growth of the Group’s product “NBP” for the financial year of 2019. The Board wishes to state that the analyst reports fairly reflect the current view of the management. Save as disclosed above and save for any information already disseminated to the market, the Board is not aware of any reasons for the increase in the price and trading volume of the shares of the Company today.

The Board also confirms that there are no negotiations or agreements relating to intended acquisitions or realisations which are discloseable under Rule 13.23 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). Neither is the Board aware of any matter discloseable under the general obligation imposed by Rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board of the Company, the directors of which individually and jointly accept responsibility for the accuracy of this statement.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 10 January 2019

As at the date of this announcement, the Board comprises Mr. Cai Dongchen, Mr. Wang Zhenguo, Mr. Pan Weidong, Mr. Wang Huaiyu, Dr. Lu Hua, Dr. Li Chunlei, Mr. Zhang Cuilong, Dr. Wang Qingxi and Mr. Chak Kin Man as executive directors; Mr. Lee Ka Sze, Carmelo as non-executive director and Mr. Chan Siu Keung, Leonard, Mr. Wang Bo, Professor Lo Yuk Lam, Dr. Yu Jinming and Mr. Chen Chuan as independent non-executive directors.